Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease

Aim To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium‐glucose co‐transporters 1 and 2, in adults with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3). Materials and Methods This phase 3, randomized, placebo‐controlled trial evaluated sotagliflozin 200 and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2023-06, Vol.25 (6), p.1646-1657
Hauptverfasser:	Cherney, David Z. I., Ferrannini, Ele, Umpierrez, Guillermo E., Peters, Anne L., Rosenstock, Julio, Powell, David R., Davies, Michael J., Banks, Phillip, Agarwal, Rajiv
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Albuminuria - drug therapy antihyperglycaemic therapy Blood pressure Body weight Creatinine Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Glomerular filtration rate Glycated Hemoglobin Humans Kidney diseases Placebos Renal Insufficiency, Chronic - chemically induced Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Safety severe renal impairment SGLT inhibitors Sodium-Glucose Transporter 2 Inhibitors - adverse effects sotagliflozin stage 3 chronic kidney disease type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!